Shenzhen New Industries Biomedical Engineering Co., Ltd. (SHE:300832)
China · Delayed Price · Currency is CNY 46.89
-1.06 (-2.21%)
Aug 4, 2026, 3:04 PM CST
SHE:300832 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 4,581 | 4,577 | 4,535 | 3,930 | 3,047 | 2,545 |
Revenue Growth | -1.25% | 0.91% | 15.42% | 28.97% | 19.70% | 15.97% |
Gross Profit Gross Profit Growth | 3,234 | 3,170 | 3,269 | 2,866 | 2,141 | 1,811 |
Operating Income Operating Income Growth | 1,818 | 1,773 | 1,933 | 1,739 | 1,333 | 1,058 |
Net Income Net Income Growth | 1,625 | 1,620 | 1,828 | 1,654 | 1,328 | 973.7 |
Earnings Per Share EPS Growth | 2.07 | 2.06 | 2.33 | 2.10 | 1.69 | 1.24 |
EPS Growth | -11.68% | -11.39% | 10.59% | 24.61% | 36.32% | -1.03% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
In Vitro Diagnostic In Vitro Diagnostic Growth | 4,575 | 4,571 | 4,527 | 3,920 | 3,047 | 2,545 |
Unallocated Other Business Unallocated Other Business Growth | - | 6.08 | 8.2 | 9.91 | - | - |
Total Total Growth | 4,581 | 4,577 | 4,535 | 3,930 | 3,047 | 2,545 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 2,423 | 3,390 | 2,718 | 3,404 | 3,407 | 3,424 |
Total Debt Total Debt Growth | 3.72 | 3.68 | 4.1 | 5.18 | 2.22 | 2.24 |
Net Cash (Debt) Net Cash Growth | 2,420 | 3,387 | 2,714 | 3,399 | 3,405 | 3,422 |
Net Cash Growth | -2.21% | 24.79% | -20.16% | -0.17% | -0.49% | 1.40% |
Net Cash Per Share Net Cash Per Share Growth | 3.08 | 4.31 | 3.45 | 4.33 | 4.33 | 4.35 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 1,863 | 1,522 | 1,356 | 1,418 | 962.39 | 773.22 |
Capital Expenditures CapEx Growth | -342.84 | -311.44 | -439.2 | -322.2 | -403.22 | -342.94 |
Free Cash Flow Free Cash Flow Growth | 1,520 | 1,211 | 917.24 | 1,096 | 559.17 | 430.28 |
Free Cash Flow Growth | 101.73% | 32.02% | -16.32% | 96.02% | 29.96% | -40.39% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Gross Margin | 70.60% | 69.25% | 72.07% | 72.93% | 70.26% | 71.15% |
Operating Margin | 39.69% | 38.74% | 42.61% | 44.24% | 43.74% | 41.55% |
Pretax Margin | 40.78% | 40.54% | 46.15% | 48.17% | 49.27% | 44.61% |
Profit Margin | 35.47% | 35.40% | 40.31% | 42.08% | 43.58% | 38.25% |
FCF Margin | 33.18% | 26.46% | 20.22% | 27.89% | 18.35% | 16.90% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Dividend Per Share Dividend Per Share Growth | 1.200 | 1.200 | 1.300 | 1.000 | 0.700 | 0.600 |
Dividend Per Share Growth | -7.69% | -7.69% | 30.00% | 42.86% | 16.67% | -54.40% |
Dividend Yield | 2.51% | 2.19% | 1.93% | 1.36% | 1.50% | 1.49% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 23.19 | 27.28 | 30.45 | 37.16 | 29.68 | 35.59 |
Forward PE | 20.41 | 24.30 | 25.23 | 31.02 | 27.83 | 28.70 |
P/FCF Ratio | 24.79 | 36.50 | 60.69 | 56.06 | 70.49 | 80.54 |
PS Ratio | 8.22 | 9.66 | 12.27 | 15.64 | 12.94 | 13.61 |